Blockbuster GLP-1 medications like Ozempic and Mounjaro might sharpen your figure, but they could also cloud your vision in ...
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
4d
Stockhead on MSNOzempic’s PBS push could shake up ASX food stocks, and here’s howBig pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results